

ABHD12 RABBIT PAB

货号: S216902

产品全名: ABHD12 兔多抗

基因符号 PHARC; ABHD12A; BEM46L2; C20orf22; dJ965G21.2

UNIPROT ID: Q8N2K0 (Gene Accession - BC014049)

背景: This gene encodes an enzyme that catalyzes the hydrolysis of 2-arachidonoyl glycerol (2-AG), the main endocannabinoid lipid transmitter that acts on cannabinoid receptors, CB1 and CB2. The endocannabinoid system is involved in a wide range of physiological processes, including neurotransmission, mood, appetite, pain appreciation, addiction behavior, and inflammation. Mutations in this gene are associated with the neurodegenerative disease, PHARC (polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract), resulting from an inborn error of endocannabinoid metabolism. Alternatively spliced transcript variants encoding different isoforms have been noted for this gene.

抗原: Fusion protein of human ABHD12

经过测试的应用: ELISA, IHC

推荐稀释比: IHC: 25-100; ELISA: 2000-5000

种属反应性: Rabbit

克隆性: Rabbit Polyclonal

亚型: Immunogen-specific rabbit IgG


纯化: Antigen affinity purification

种属反应性: Human, Mouse, Rat


成分: PBS (without Mg²⁺ and Ca²⁺), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Metabolism


储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human thyroid cancer tissue using 216902(ABHD12 Antibody) at a dilution of 1/30(Cytoplasm).



In comparison with the IHC on the left, the same paraffin-embedded Human thyroid cancer tissue is first treated with the fusion protein and then with 216902(Anti-ABHD12 Antibody) at dilution 1/30.



The image on the left is immunohistochemistry of paraffin-embedded Human liver cancer tissue using 216902(Anti-ABHD12 Antibody) at a dilution of 1/30.



In comparison with the IHC on the left, the same paraffin-embedded Human liver cancer tissue is first treated with fusion protein and then with D221449(Anti-ABHD12 Antibody) at dilution 1/30.



Product Description

Pioneering GTPase and Oncogene Product Development since 2010
